COPY OF PAPERS . ORIGINALLY FILED

I hereby certify that this correspondence is being deposited with the United States Posta Services on the date set forth below as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Date of Signature (and Deposit:_

Attorney of Record

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE SEP 1 2 2002

Applicant:

Hector F. DeLuca

Serial No.:

10/074,102

TECH CENTER 1600/2900

Filed:

February 12, 2002

For:

PREPARATIONS AND USE OF AN AH

RECEPTOR LIGAND, 2-(1'H-INDOLE-3'-CARBONYL) -THIAZOLE-4-CARBOXYLIC ACID

METHYL ESTER

Group Art Unit:

1645

Examiner:

Commissioner For Patents Washington, D.C.

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. 1.98, enclosed herewith is a list of documents which the Applicants in the aboveidentified patent application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this patent application.

Other Documents

- A. J. Philips, et al., "Synthesis of Functionalized Oxazolines and Oxazoles with DAST and Deoxo-Fluor," Organic Letter 2(8):1165-1168, 2000.
- R. Susilo, et al., "Formation of Thiazolidine-4-Carboxylic Acid Represents a Main Metabolic Pathway of 5-

Hydroxytryptamine in Rat Brain, J. Neurochemistry 52(6):1793-1800, 1989.

The enclosed documents are part of a PCT

International Search Report that issued in a related PCT

application. Applicants state that each item of

information contained in the Information Disclosure

Statement was cited in a communication from a foreign

patent office in a counterpart foreign application not

more than three months prior to the filing of this

Information Disclosure Statement.

No fees are believed necessary to enter this Statement. However, if any fees are necessary please charge Deposit Account 17-0055.

Respectfully submitted,

Hector F. DeLuca

Spl August 3, 2002

By:

Jean C. Baker

Reg. No. 35,433

Quarles & Brady LLP 411 East Wisconsin Avenue

Milwaukee, WI 53202-4497

(414) 277-5709

CGPY OF PAPERS ORIGINALLY FILED

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

SEP 0 9 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

Complete if Known				
Application Number	10/074,102			
Filing Date	February 2, 2002			
First Named Inventor	Hector F. DeLuca			
Group Art Unit	1645			
Examiner Name				
Attorney Docket Number	960296.97206			

				U.S. PATENT DOCL	MENTS		
Examiner	Cite	U.S. Patent Document Kind Code²		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials			of Cited Document MM-DD-YYYY		Figures Appear		
						RECEIVED	
						SEP 1 2 2002	
						TECH CENTER 1600/2900	
						EUH ULIH LIH 1000	
	1						
	+-	+					

				FORE	GN PATENT DOCUMENT	rs		
Examiner	Cite	Foreign Patent Document Kind Code ⁵		Cument Kind Code ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
Initials*	No.1	Office ³	Number ⁴	(if known)		MM-DD-1111	rigures Appear	
								1_
		╂╾┼╼						╀
		 						+
						 		+
								1
								\perp
	<u> </u>	+-+						┸

_		Date		I
ſ	Examiner	Cons	sidered	
I	Signature	MPEP 609	Draw line t	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

COPY OF PAPERS ORIGINALLY FILED

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE or a confection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to re-Complete if Known 10/074,102 Substitute for form 1449B/PTO **Application Number** February 2, 2002 INFORMATION DISCLOSURE Filing Date Hector F. DeLuca First Named Inventor STATEMENT BY APPLICANT 1645 Group Art Unit Examiner Name (use as many sheets as necessary) Attorney Docket Number 960296.97206

	(us	se as many		1 0		Attorney Docket Number	960296.97206	
Sheet	2			2		ļ		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Include name of the author (in CAPITAL LETTERS), its of the transport of the page(s), volume-issue number(s),						T ²		
Everying Cite 1 item (book, magazine, journal, serial, symptomy where published.							+	
nitials'	ls' No.1 Descriptionalized Oxazolines and Oxazoles with DAST							
	}	A. J. Phil	lips,	et al., "Syl	anic Letter 2	2(8):1165-1168, 2000.		
	and Denxo-Fluor, Organic Letter =(0)							
	-	D Susile	a et	al. "Form	ation of Thia	azolidine-4-Carboxylic F	L Neurochemistry	
	R. Susilo, et al., "Formation of Thiazolidine-4-Carboxylic Acid Represents a Main Metabolic Pathway of 5-Hydroxytryptamine in Rat Brain," J. Neurochemistry						J. Negrocitoring	
	1	52/61-17	03	1900 1090	<u> </u>			
								- }
							RECEIVED	
	+-	 					RECLIVED	1
		1					SEP 1-2-2002	
	١.							
	T	T					TECH CENTER 1600/29	001
Ì	1						TECH CENTER TOUTES	
 	+-					<u></u>	1,20	
1		1						
l .	1							
								- 1
1	-							
1 _								1
1	- 1							
<u> </u>								- 1
l l	- 1	1						
							Ì	
							1	
1	- 1	- 1						
1								
1								
	-+							1
1								
1								Ì
- 1	1	ł						
1	1	ŀ						

			Daio	
1	Examiner		Considered	
I	Signature	nitial if reference considered, whether or not citation is in conformance with MPEP 60	o Draw line throu	igh citation if not in conformance and not
		whether or not citation is in conformance with MPEP of	. Dian	•
	*EXAMINER: In	nitial if reference considered, who are munication to applicant.		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

5291049_1.PDF

considered. Include copy of this form with next communication to applicant. ¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.